AAAAAA

   
Results: 1-25 | 26-50 | 51-67
Results: 26-50/67
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin
Authors: Kakolyris, S Kouroussis, C Kalbakis, K Mavroudis, D Souglakos, J Vardakis, N Kremos, S Georgoulias, V
Citation: S. Kakolyris et al., Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin, ANN ONCOL, 11(6), 2000, pp. 757-760
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
Authors: Mavroudis, D Alexopoulos, A Ziras, N Malamos, N Kouroussis, C Kakolyris, S Agelaki, S Kalbakis, K Tsavaris, N Potamianou, A Rigatos, G Georgoulias, V
Citation: D. Mavroudis et al., Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study, ANN ONCOL, 11(10), 2000, pp. 1249-1254
Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? In reply
Authors: Georgoulias, V
Citation: V. Georgoulias, Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? In reply, J CL ONCOL, 18(2), 2000, pp. 445-446
Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study
Authors: Koukourakis, MI Kyrias, G Kakolyris, S Kouroussis, C Frangiadaki, C Giatromanolaki, A Retalis, G Georgoulias, V
Citation: Mi. Koukourakis et al., Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study, J CL ONCOL, 18(11), 2000, pp. 2226-2233
A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Authors: Kouroussis, C Agelaki, S Mavroudis, D Souglakos, J Kakolyris, S Kalbakis, K Vardakis, N Reppa, D Hatzidaki, D Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose escalation study of weekly docetaxel in patients with advanced solid tumors, CANC CHEMOT, 46(6), 2000, pp. 488-492
High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - Rationale for combination with radiotherapy
Authors: Koukourakis, MI Koukouraki, S Giatromanolaki, A Kakolyris, S Georgoulias, V Velidaki, A Archimandritis, S Karkavitsas, NN
Citation: Mi. Koukourakis et al., High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - Rationale for combination with radiotherapy, ACTA ONCOL, 39(2), 2000, pp. 207-211
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial
Authors: Mavroudis, D Kourousis, C Androulakis, N Kalbakis, K Agelaki, S Kakolyris, S Souglakos, J Sarra, E Vardakis, N Hatzidaki, D Sarmonis, G Georgoulias, V
Citation: D. Mavroudis et al., Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial, AM J CL ONC, 23(4), 2000, pp. 341-344
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy - A report of five cases
Authors: Kouroussis, C Samonis, G Androulakis, N Souglakos, J Voloudaki, A Dimopoulos, MA Kotsakis, T Kakolyris, S Kalbakis, K Georgoulias, V
Citation: C. Kouroussis et al., Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy - A report of five cases, AM J CL ONC, 23(3), 2000, pp. 309-313
Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin'slymphomas
Authors: Kanavaros, P Stefanaki, K Vlachonikolis, J Eliopoulos, C Kakolyris, S Rontogianni, D Gorgoulis, V Georgoulias, V
Citation: P. Kanavaros et al., Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin'slymphomas, HIST HISTOP, 15(2), 2000, pp. 445-453
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy
Authors: Kakolyris, S Souglakos, J Agelaki, S Kourousis, C Mavroudis, D Sarra, E Malliotakis, P Georgoulias, V
Citation: S. Kakolyris et al., A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy, LUNG CANC, 30(3), 2000, pp. 193-198
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report
Authors: Mavroudis, D Kourousis, C Kakolyris, S Agelaki, S Kalbakis, K Androulakis, N Souglakos, J Vardakis, N Samonis, G Georgoulias, V
Citation: D. Mavroudis et al., Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report, SEMIN ONCOL, 27(1), 2000, pp. 25-30
Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study
Authors: Dimopoulos, MA Papadimitriou, CA Georgoulias, V Moulopoulos, LA Aravantinos, G Gika, D Karpathios, S Stamatelopoulos, S
Citation: Ma. Dimopoulos et al., Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study, GYNECOL ONC, 78(1), 2000, pp. 52-57
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer
Authors: Koukourakis, MI Giatromanolaki, A Thorpe, PE Brekken, RA Sivridis, E Kakolyris, S Georgoulias, V Gatter, KC Harris, AL
Citation: Mi. Koukourakis et al., Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer, CANCER RES, 60(11), 2000, pp. 3088-3095
Docetaxel-induced lymphopenia in patients with solid tumors - A prospective phenotypic analysis
Authors: Kotsakis, A Sarra, E Peraki, M Koukourakis, M Apostolaki, S Souglakos, J Mavromanomakis, E Vlachonikolis, J Georgoulias, V
Citation: A. Kotsakis et al., Docetaxel-induced lymphopenia in patients with solid tumors - A prospective phenotypic analysis, CANCER, 89(6), 2000, pp. 1380-1386
Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectaladenocarcinomas
Authors: Kanavaros, P Stefanaki, K Valassiadou, K Vlachonikolis, J Mavromanolakis, M Vlychou, M Kakolyris, S Gorgoulis, V Tzardi, M Georgoulias, V
Citation: P. Kanavaros et al., Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectaladenocarcinomas, MED ONCOL, 16(1), 1999, pp. 23-30
Irinotecan (CPT-11) in patients with advanced colorectal cancer previouslytreated with 5-fluorouracil-based chemotherapy
Authors: Aravantinos, G Skarlos, DV Kosmidis, P Georgoulias, V Sgouros, I Bafaloukos, D Androulakis, N Florou, S Fountzilas, G
Citation: G. Aravantinos et al., Irinotecan (CPT-11) in patients with advanced colorectal cancer previouslytreated with 5-fluorouracil-based chemotherapy, CR R ONC H, 32(3), 1999, pp. 209-219
Intratumoral angiogenesis: A new prognostic indicator for stage I endometrial adenocarcinomas?
Authors: Giatromanolaki, A Sivridis, E Koukourakis, MI Georgoulias, V Gatter, KC Harris, AL
Citation: A. Giatromanolaki et al., Intratumoral angiogenesis: A new prognostic indicator for stage I endometrial adenocarcinomas?, ONCOL RES, 11(4), 1999, pp. 205-212
Increasing options in cancer therapy: current status and future prospects
Authors: Georgoulias, V Crown, JP
Citation: V. Georgoulias et Jp. Crown, Increasing options in cancer therapy: current status and future prospects, ANTI-CANC D, 10, 1999, pp. S1-S3
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
Authors: Kouroussis, C Xydakis, E Potamianou, A Giannakakis, T Kakolyris, S Agelaki, S Sara, E Malamos, N Alexopoulos, A Mavroudis, D Samonis, G Papadouris, S Georgoulias, V Panagos, G
Citation: C. Kouroussis et al., Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study, ANN ONCOL, 10(5), 1999, pp. 547-552
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial
Authors: Mavroudis, D Malamos, N Alexopoulos, A Kourousis, C Agelaki, S Sarra, E Potamianou, A Kosmas, C Rigatos, G Giannakakis, T Kalbakis, K Apostolaki, F Vlachonicolis, J Kakolyris, S Samonis, G Georgoulias, V
Citation: D. Mavroudis et al., Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial, ANN ONCOL, 10(2), 1999, pp. 211-215
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group
Authors: Dimopoulos, MA Bakoyannis, C Georgoulias, V Papadimitriou, C Moulopoulos, LA Deliveliotis, C Karayannis, A Varkarakis, I Aravantinos, G Zervas, A Pantazopoulos, D Fountzilas, G Bamias, A Kyriakakis, Z Anagnostopoulos, A Giannopoulos, A Kosmidis, P
Citation: Ma. Dimopoulos et al., Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group, ANN ONCOL, 10(11), 1999, pp. 1385-1388
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study
Authors: Androulakis, N Kourousis, C Dimopoulos, MA Samelis, G Kakolyris, S Tsavaris, N Genatas, K Aravantinos, G Papadimitriou, C Karabekios, S Stathopoulos, GP Georgoulias, V
Citation: N. Androulakis et al., Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study, J CL ONCOL, 17(6), 1999, pp. 1779-1785
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
Authors: Kouroussis, C Androulakis, N Kakolyris, S Souglakos, J Kotsakis, T Mavroudis, D Katsogridakis, K Vardakis, N Hatzidaki, D Samonis, G Vlachonikolis, J Georgoulias, V
Citation: C. Kouroussis et al., Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer, J CL ONCOL, 17(3), 1999, pp. 862-869
Front-line treatment of advanced non-small-cell lung cancer with docetaxeland gemcitabine: A multicenter phase II trial
Authors: Georgoulias, V Kouroussis, C Androulakis, N Kakolyris, S Dimopoulos, MA Papadakis, E Bouros, D Apostolopoulou, F Papadimitriou, C Agelidou, A Hatzakis, K Kalbakis, K Kotsakis, A Vardakis, N Vlachonicolis, J
Citation: V. Georgoulias et al., Front-line treatment of advanced non-small-cell lung cancer with docetaxeland gemcitabine: A multicenter phase II trial, J CL ONCOL, 17(3), 1999, pp. 914-920
Concurrent twice-a-week docetaxel and radiotherapy: A dose escalation trial with immunological toxicity evaluation
Authors: Koukourakis, MI Giatromanolaki, A Schiza, S Kakolyris, S Georgoulias, V
Citation: Mi. Koukourakis et al., Concurrent twice-a-week docetaxel and radiotherapy: A dose escalation trial with immunological toxicity evaluation, INT J RAD O, 43(1), 1999, pp. 107-114
Risultati: 1-25 | 26-50 | 51-67